Lifeward sets Oct. 30, 2026 shareholder meeting

Q: When will Lifeward Ltd. (LFWD) hold its 2026 Annual and Extraordinary General Meeting?

Lifeward Ltd. has set October 30, 2026 as the date for its 2026 Annual and Extraordinary General Meeting of Shareholders. The meeting date is more than 30 days after the anniversary of the 2025 annual general meeting.

Q: Which rules govern shareholder proposals and nominations at Lifeward (LFWD)?

Shareholder proposals and nominations must comply with SEC rules, the Israel Companies Law 5759-1999, and Lifeward’s Articles of Association, as applicable, in addition to meeting the stated deadline and delivery requirements.

Q: Does this Lifeward (LFWD) disclosure involve any financing or major transaction?

No. The disclosure concerns the scheduling of the 2026 Annual and Extraordinary General Meeting and the deadline and conditions for shareholder proposals and director nominations, without announcing financings or major transactions.

Lifeward Ltd. sets its 2026 annual and extraordinary shareholder meeting for October 30, 2026 and establishes a September 23, 2026 deadline for Rule 14a-8 proposals.

Available on EDGAR 09/15/2026 - 05:14 PM EDT Accepted by SEC EDGAR 09/15/2026 - 05:13 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lifeward Ltd. (LFWD) announces that its 2026 Annual and Extraordinary General Meeting of Shareholders will be held on October 30, 2026. Because this date is more than 30 days after the prior year’s annual meeting anniversary, shareholders seeking to include proposals in the company’s proxy materials under Rule 14a-8 must ensure their proposals are received at the company’s Israeli office by September 23, 2026. Proposals and director nominations must also comply with SEC rules, the Israel Companies Law 5759-1999, and Lifeward’s Articles of Association.

8-K Event Classification

Item 5.08 — Shareholder Director Nominations

1 item

Item 5.08 Shareholder Director Nominations Governance

Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.

Key Figures

Annual Meeting date: October 30, 2026 Rule 14a-8 proposal deadline: September 23, 2026 Principal executive offices ZIP code: 01749

3 metrics

Annual Meeting date October 30, 2026 Date set for Lifeward Ltd.’s 2026 Annual and Extraordinary General Meeting of Shareholders

Rule 14a-8 proposal deadline September 23, 2026 Last date for shareholder proposals to be received for inclusion in 2026 proxy materials

Principal executive offices ZIP code 01749 ZIP code for Lifeward’s principal executive offices at 2 Cabot Rd., Hudson, MA

Key Terms

Rule 14a-8, Schedule 14N, Israel Companies Law 5759-1999, Articles of Association

4 terms

Rule 14a-8 regulatory

"inclusion in the Company’s proxy materials for the Annual Meeting pursuant to Rule 14a-8"

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

Schedule 14N regulatory

"including any notice on Schedule 14N, which the Company has determined"

Israel Companies Law 5759-1999 regulatory

"rules and regulations promulgated by the Securities and Exchange Commission, the Israel Companies Law 5759-1999"

Articles of Association regulatory

"and the Company’s Articles of Association, as applicable"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lifeward Ltd. (LFWD) hold its 2026 Annual and Extraordinary General Meeting?

Lifeward Ltd. has set October 30, 2026 as the date for its 2026 Annual and Extraordinary General Meeting of Shareholders. The meeting date is more than 30 days after the anniversary of the 2025 annual general meeting.

What is the deadline for shareholder proposals for Lifeward (LFWD) under Rule 14a-8?

Shareholders must ensure proposals for inclusion in Lifeward’s 2026 proxy materials under Rule 14a-8 are received by the Interim Chief Executive Officer on or before September 23, 2026 at the company’s office in Yokneam Ilit, Israel.

Where must Lifeward (LFWD) shareholder proposals be delivered?

Proposals must be received by the Interim Chief Executive Officer at Lifeward Ltd., 3 Hatnufa Street, 6th Floor, Yokneam Ilit, Israel, by the September 23, 2026 deadline for inclusion in the 2026 proxy materials.

Which rules govern shareholder proposals and nominations at Lifeward (LFWD)?

Shareholder proposals and nominations must comply with SEC rules, the Israel Companies Law 5759-1999, and Lifeward’s Articles of Association, as applicable, in addition to meeting the stated deadline and delivery requirements.

Does this Lifeward (LFWD) disclosure involve any financing or major transaction?

No. The disclosure concerns the scheduling of the 2026 Annual and Extraordinary General Meeting and the deadline and conditions for shareholder proposals and director nominations, without announcing financings or major transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2026

Lifeward Ltd.

(Exact name of registrant as specified in its charter)

Israel

001-36612

Not applicable

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(IRS Employer

Identification No.)

2 Cabot Rd., Hudson, MA		01749
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +508.251.1154

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act		Trading Symbol		Name of each exchange on which registered
Ordinary Shares, no par value		LFWD		Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.08 Shareholder Director Nominations.

The Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) has set October 30, 2026 as the date for the Company’s 2026 Annual and Extraordinary General Meeting of Shareholders (the “Annual Meeting”). Because the Annual Meeting will be held more than 30 days from the anniversary date of the Company’s 2025 annual general meeting of shareholders, shareholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials for the Annual Meeting pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, must ensure that such proposal is received by the Company’s Interim Chief Executive Officer at the Company’s office located at Lifeward Ltd., 3 Hatnufa Street, 6th Floor, Yokneam Ilit, Israel, on or before September 23, 2026, including any notice on Schedule 14N, which the Company has determined is a reasonable time before it expects to begin to print and send its proxy materials. All shareholder proposals and nominations must comply with the rules and regulations promulgated by the Securities and Exchange Commission, the Israel Companies Law 5759-1999, and the Company’s Articles of Association, as applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lifeward Ltd.
Dated: September 15, 2026	By:	/s/ Almog Adar
	Name:	Almog Adar
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents